We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) to Offer Discount on Insulin from January
Read MoreHide Full Article
Pharma major Eli Lilly and Company (LLY - Free Report) , in partnership with Express Scripts Holding Company , announced that it will offer insulin products at discounted prices, starting Jan 2017, to patients via Blink Health’s mobile and web platforms.
Note that drug pricing is back in the spotlight with President-elect Donald Trump clarifying in an interview with TIME magazine that his intentions were misinterpreted and that he actually intends to target excessive drug price hikes.
This has urged diabetes pharmaceutical companies to anyhow control insulin prices. For instance, Novo Nordisk A/S (NVO - Free Report) plans limit price increases on insulin products to a single-digit percentage per year.
Since Trump’s comments in the aforesaid interview, Lilly’s share price has inched up a mere 0.3%, underperforming the 2.5% gain witnessed by the Zacks classified Large-Cap Pharma industry. The company’s shares have tanked 19.8% year to date, comparing unfavorably with a decline of 6.3% for the industry.
Coming back to the latest news, Lilly's initiative will reduce the price of its insulins by 40% for patients who pay the full retail price at the pharmacies, benefitting especially those who have no insurance or are in the deductible phase of their high-deductible insurance plans.
The discount program includes all presentations of Humalog (Humalog Mix50/50, Humalog Mix75/25) – indicated to improve glycemic control in adults and children with diabetes mellitus; all Humulin U100 formulations – for diabetes; and Basaglar – indicated to control high blood sugar in adults and children with type I diabetes and adults with type II diabetes.
Humalog and Humulin generated U.S. sales of $1.2 billion and $640 million, respectively, in the first nine months of this year. Basaglar, on the other hand, will be launched in the U.S. on Dec 15.
An estimated 29 million people in the U.S. and 415 million people in the world have type I and type II diabetes.
Lilly currently carries a Zacks Rank #4 (Sell). Sucampo Pharmaceuticals, Inc. is a better-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $1.58 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) to Offer Discount on Insulin from January
Pharma major Eli Lilly and Company (LLY - Free Report) , in partnership with Express Scripts Holding Company , announced that it will offer insulin products at discounted prices, starting Jan 2017, to patients via Blink Health’s mobile and web platforms.
Note that drug pricing is back in the spotlight with President-elect Donald Trump clarifying in an interview with TIME magazine that his intentions were misinterpreted and that he actually intends to target excessive drug price hikes.
This has urged diabetes pharmaceutical companies to anyhow control insulin prices. For instance, Novo Nordisk A/S (NVO - Free Report) plans limit price increases on insulin products to a single-digit percentage per year.
Since Trump’s comments in the aforesaid interview, Lilly’s share price has inched up a mere 0.3%, underperforming the 2.5% gain witnessed by the Zacks classified Large-Cap Pharma industry. The company’s shares have tanked 19.8% year to date, comparing unfavorably with a decline of 6.3% for the industry.
Coming back to the latest news, Lilly's initiative will reduce the price of its insulins by 40% for patients who pay the full retail price at the pharmacies, benefitting especially those who have no insurance or are in the deductible phase of their high-deductible insurance plans.
The discount program includes all presentations of Humalog (Humalog Mix50/50, Humalog Mix75/25) – indicated to improve glycemic control in adults and children with diabetes mellitus; all Humulin U100 formulations – for diabetes; and Basaglar – indicated to control high blood sugar in adults and children with type I diabetes and adults with type II diabetes.
Humalog and Humulin generated U.S. sales of $1.2 billion and $640 million, respectively, in the first nine months of this year. Basaglar, on the other hand, will be launched in the U.S. on Dec 15.
An estimated 29 million people in the U.S. and 415 million people in the world have type I and type II diabetes.
LILLY ELI & CO Price and Consensus
LILLY ELI & CO Price and Consensus | LILLY ELI & CO Quote
Zacks Rank & Key Picks
Lilly currently carries a Zacks Rank #4 (Sell). Sucampo Pharmaceuticals, Inc. is a better-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $1.58 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>